Compare CLDI & OFAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLDI | OFAL |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Military/Government/Technical |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.7M |
| IPO Year | 2021 | 2026 |
| Metric | CLDI | OFAL |
|---|---|---|
| Price | $0.65 | $0.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 40.3K | ★ 13.6M |
| Earning Date | 11-12-2026 | 07-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $45,000.00 | ★ $716,885.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 254.88 |
| 52 Week Low | $0.09 | $0.01 |
| 52 Week High | $3.38 | $0.75 |
| Indicator | CLDI | OFAL |
|---|---|---|
| Relative Strength Index (RSI) | 26.99 | 59.19 |
| Support Level | $0.62 | $0.04 |
| Resistance Level | $1.29 | $0.38 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 14.15 | 7.20 |
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
OFA Group provides interior design, fit-out, project management and application services in Hong Kong for commercial and residential buildings. Its interior design services include consultation, conceptualized designs, layout plans, detailed design drawings and advice on budgetary considerations, space utilization, materials, fittings, furniture, appliances and other items. Its fit-out services include the installation of protective materials, partition walls, windows, decorative fittings, furniture, fixtures, plumbing systems, switches, power outlets, telephone wiring, computer outlet covers and other electrical and wiring works. The Group is transitioning from a project-based model to a subscription-based model for AI tools, real estate development and senior care infrastructure.